Adelaide Research & Scholarship: Search

Search

Results 1-7 of 7 (Search time: 0.002 seconds).

previous
1
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2006	The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL	Butler, L.; Liapis, V.; Bouralexis, S.; Welldon, K.; Hay, S.; Thai, L.; Labrinidis, A.; Tilley, W.; Findlay, D.; Evdokiou, A.
	2011	Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo	Zinonos, I.; Labrinidis, A.; Lee, M.; Liapis, V.; Hay, S.; Ponomarev, V.; Diamond, P.; Findlay, D.; Zannettino, A.; Evdokiou, A.
	2010	Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model	Labrinidis, A.; Hay, S.; Liapis, V.; Findlay, D.; Evdokiou, A.
	2008	Does Apo2LTRAIL play any physiologic role in osteoclastogenesis?	Labrinidis, A.; Liapis, V.; Thai, L.; Atkins, G.; Vincent, C.; Hay, S.; Sims, N.; Zannettino, A.; Findlay, D.; Evdokiou, A.
	2009	Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer	Zinonos, I.; Labrinidis, A.; Lee, M.; Liapis, V.; Hay, S.; Ponomarev, V.; Diamond, P.; Zannettino, A.; Findlay, D.; Evdokiou, A.
	2009	Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma	Labrinidis, A.; Diamond, P.; Martin, S.; Hay, S.; Liapis, V.; Zinonos, I.; Sims, N.; Atkins, G.; Vincent, C.; Ponomarev, V.; Findlay, D.; Zannettino, A.; Evdokiou, A.
	2009	Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model	Labrinidis, A.; Hay, S.; Liapis, V.; Ponomarev, V.; Findlay, D.; Evdokiou, A.